undamentalytics Newsletter
Sign in

Ideaya Biosciences, Inc. income statement

In fiscal 2025, Ideaya Biosciences, Inc. reported revenue of $219m, up 3024.4% on the year before, operating income of −$159m (a -72.8% margin) and net income of −$114m, or −$1.28 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue0202851237219234
Research and development34405890130295315374
General and administrative1015202428396377
Operating income−44−35−50−63−134−327−159−217
Income tax00000000
Net income−42−34−50−59−113−274−114−175
Diluted EPS−$1.68−$1.40−$1.41−$1.42−$1.96−$3.36−$1.28−$1.96
Diluted shares (average)25m25m35m41m58m82m88m89m
EBITDA−43−34−49−60−132−325−157−214

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: IDYA vs PBYIANAB vs IDYAIDYA vs RYTMAKBA vs IDYA

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Ideaya Biosciences, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Ideaya Biosciences, Inc.